trial · primary record
Valemetostat
Extensive-stage Small-cell Lung Cancer
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2027-01 |
| Primary endpoint | Determine Phase II dose (RP2D) |
| Registry ID | NCT06807632 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:44:24.459Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06807632
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.